REG - Genflow Biosciences - Company Share Purchase by CEO

Genflow BiosciencesAnnouncement

19/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220719:nRSS8872Sa&default-theme=true

RNS Number : 8872S  Genflow Biosciences PLC  19 July 2022

 

19 July 2022

 

Genflow Biosciences Plc

 

("Genflow" or "the Company")

 

Company Share Purchase by CEO

Genflow Biosciences (LSE: GENF), a UK-based biotechnology company focused on
longevity and the development of therapies to counteract the effects of aging
and diseases associated with advanced age,

announces that it was notified on 15 July 2022 and 18 July 2022, that Eric
Leire, a director of the Company, purchased the following Ordinary Shares:

 

 PDMR / Person closely associated  Total Number of Ordinary Shares Purchased  Weighted Average Price per Ordinary Share  Resultant Shareholding  Percentage Of The Total Voting Rights of the Company
 Eric Leire                        308,999                                    3.03p                                      120,308,999             41.13

 

Notifications have been made in accordance with the requirements of the EU
Market Abuse Regulation in respect of the PDMRs and further details can be
found by following this link: https://genflowbio.com/investors/news-releases/
(https://genflowbio.com/investors/news-releases/)

The information communicated in this announcement is inside information for
the purposes of Article 7 of Regulation 596/2014.

 

For further information please contact:

 

 Genflow Biosciences
 Dr Eric Leire                       via Tancredi +44 203 434 2330

 Chief Executive
 Clear Capital
 Corporate Broker

 Jonathan Critchley                  +44 203 869 6086

 Keith Swann

                                     +44 203 897 0981
 Tancredi Intelligent Communication

 Media Relations
 Salamander Davoudi                  +44 7957 549 906

 Helen Humphrey                      +44 7449 226 720

 Benedetta Negri da Oleggio          +44 7838 029 970

                                     genflowbio@tancredigroup.com

 

About Genflow Biosciences

 

Genflow is a UK-based biotechnology company established in 2020. The Company
is developing gene therapies designed to target the aging process and to
reduce and delay the incidence of age-related diseases. This will be done
through novel therapeutics targeting aging in humans by using adeno-associated
virus ("AAV") vectors to deliver copies of the Sirtuin-6 ("SIRT6") gene
variant that is found in centenarians into cells.

 

Its mission is to increase our understanding of the factors that control and
impact lifespan. Genflow researchs, develops, and commercialises therapeutic
solutions to lengthen health span, the amount of time we live in good health,
creating biological interventions that enable longer and healthier lives.
Genflow is dedicated to the development and commercialisation of novel
therapeutics targeting aging in dogs and humans. By treating aging, Genflow
can contribute to a decrease in healthcare costs and lessen the emotional and
societal burden that comes with an aging population.

 

To learn more visit www.genflowbio.com (http://www.genflowbio.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHEANXPFANAEFA